Prevalence and Trends of Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter Species Isolated from Clinical Specimens at the Ethiopian Public Health Institute, Addis Ababa, Ethiopia: A Retrospective Analysis

References

• Mehrad B, Clark NM, Zhanel GG, Lynch JP. Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest. 2015;147(5):1413–1421. doi:10.1378/chest.14-2171
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria types of infections NIH public access. N Engl J Med. 2010;362(19):1804–1813. doi:10.1056/NEJMra0904124.Hospital-Acquired
   PubMed Web of Science ®Google Scholar
• Sartelli M, Mckimm J, Bakar MA, Abu Bakar MB. Health care-associated infections – an overview. Infect Drug Resist. 2018;11:2321–2333. doi:10.2147/IDR.S177247
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23(4):332–339. doi:10.1097/QCO.0b013e32833ae38b
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–762. doi:10.1016/S1473-3099(08)70279-2
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43(SUPPL. 2):49–56. doi:10.1086/504477
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). M100 Performance Standards for Antimicrobial Susceptibility Testing. Vol. M100-Ed32. Clinical and Laboratory Standards Institute (CLSI); 2021.
   Google Scholar
• Palacios-Baena ZR, Giannella M, Manissero D, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27(2):228–235. doi:10.1016/j.cmi.2020.10.016
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34(5):634–640. doi:10.1086/338782
   PubMed Web of Science ®Google Scholar
• Grossi P, Gasperina DD. Treatment of Pseudomonas aeruginosa infection in critically ill patients. Expert Rev Anti Infect Ther. 2006;4(4):639–662. doi:10.1586/14787210.4.4.639
   PubMedGoogle Scholar
• Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21. doi:10.1177/2049936115621709
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8(1):71–93. doi:10.1586/eri.09.108
   PubMed Web of Science ®Google Scholar
• Zaidi AKM, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. Lancet. 2005;365(9465):1175–1188. doi:10.1016/S0140-6736(05)71881-X
   PubMed Web of Science ®Google Scholar
• Allegranzi B, Nejad SB, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228–241. doi:10.1016/S0140-6736(10)61458-4
   PubMed Web of Science ®Google Scholar
• Bitew A, Adane A, Abdeta A. Bacteriological spectrum, extended ‑ spectrum β ‑ lactamase production and antimicrobial resistance pattern among patients with bloodstream infection in Addis Ababa. Sci Rep. 2023;13(1):1–11. doi:10.1038/s41598-023-29337-x
   PubMed Web of Science ®Google Scholar
• Mekonnen H, Seid A, Fenta GM, Gebrecherkos T, Hasnain SE. Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, NorthEast Ethiopia. A cross-sectional study. PLoS One. 2021;16:1–17. doi:10.1371/journal.pone.0257272
   Web of Science ®Google Scholar
• Motbainor H, Bereded F, Mulu W. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study. BMC Infect Dis. 2020;20(1):1–11. doi:10.1186/s12879-020-4811-8
   Web of Science ®Google Scholar
• Tilahun M, Gedefie A, Bisetegn H, Debash H. Emergence of high prevalence of extended-spectrum beta-lactamase and carbapenemase producing Acinetobacter species and Pseudomonas aeruginosa among hospitalized patients at Dessie comprehensive specialized hospital, North-East Ethiopia. Infect Drug Resist. 2022;15:895–911. doi:10.2147/IDR.S358116
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521–S528. doi:10.1093/cid/ciz824
   PubMed Web of Science ®Google Scholar
• Ssekatawa K, Byarugaba DK, Wampande E, Ejobi F. A systematic review: the current status of carbapenem resistance in East Africa. BMC Res Notes. 2018;11(1):1–9. doi:10.1186/s13104-018-3738-2
   PubMedGoogle Scholar
• Ayenew Z, Tigabu E, Syoum E, Ebrahim S, Assefa D, Tsige E. Multidrug resistance pattern of Acinetobacter species isolated from clinical specimens referred to the Ethiopian Public Health Institute: 2014 to 2018 trend anaylsis. PLoS One. 2021;16:1–12. doi:10.1371/journal.pone.0250896
   Web of Science ®Google Scholar
• Alemayehu T, Asnake S, Tadesse B, et al. Phenotypic detection of carbapenem-resistant gram-negative bacilli from a clinical specimen in sidama, Ethiopia: a cross-sectional study. Infect Drug Resist. 2021;14:369–380. doi:10.2147/IDR.S289763
   PubMed Web of Science ®Google Scholar
• Tufa TB, Mackenzie CR, Orth HM, et al. Prevalence and characterization of antimicrobial resistance among gram-negative bacteria isolated from febrile hospitalized patients in central Ethiopia. Antimicrob Resist Infect Control. 2022;11(1):1–12. doi:10.1186/s13756-022-01053-7
   PubMed Web of Science ®Google Scholar
• Abda EM, Adugna Z, Assefa A. Elevated level of imipenem-resistant gram-negative bacteria isolated from patients attending health centers in North Gondar, Ethiopia. Infect Drug Resist. 2020;13:4509–4517. doi:10.2147/IDR.S287700
   PubMed Web of Science ®Google Scholar
• Sewunet T, Asrat D, Woldeamanuel Y, Aseffa A, Giske CG. Molecular epidemiology and antimicrobial susceptibility of Pseudomonas spp. and Acinetobacter spp. from clinical samples at Jimma Medical Center, Ethiopia. Front Microbiol. 2022;13. doi:10.3389/fmicb.2022.951857
   PubMed Web of Science ®Google Scholar
• Amy LL. Clinical Microbiology Procedures Handbook. 4th ed. Amy LL, editor. Washington DC: American society for microbiology press; 2016. doi:10.1128/9781555818814
   Google Scholar
• Kock MM, Bellomo AN, Storm N, Ehlers MM. Prevalence of carbapenem resistance genes in Acinetobacter baumannii isolated from clinical specimens obtained from an academic hospital in South Africa. South Afr J Epidemiol Infect. 2013;28(1):28–32. doi:10.1080/10158782.2013.11441516
   Google Scholar
• Kaluba CK, Samutela MT, Kapesa C, et al. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter species at a large tertiary referral hospital in Lusaka, Zambia. Sci Afr. 2021;13:e00908. doi:10.1016/j.sciaf.2021.e00908
   Google Scholar
• Ramette A, Kronenberg A, Burnens A, et al. Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland. BMC Infect Dis. 2018;18(1):1–6. doi:10.1186/s12879-018-3061-5
   PubMedGoogle Scholar
• Lin KY, Lauderdale TL, Wang JT, Chang SC. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: prevalence, risk factors, and impact on outcome of infections. J Microbiol Immunol Infect. 2016;49(1):52–59. doi:10.1016/j.jmii.2014.01.005
   PubMedGoogle Scholar
• Liang C, Zhang X, Zhou L, Meng G, Zhong L, Peng P. Trends and correlation between antibacterial consumption and carbapenem resistance in gram-negative bacteria in a tertiary hospital in China from 2012 to 2019. BMC Infect Dis. 2021;21(1):1–9. doi:10.1186/s12879-021-06140-5
   PubMed Web of Science ®Google Scholar
• Gupta V, Ye G, Olesky M, Lawrence K, Murray J, Yu K. Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013–2017. BMC Infect Dis. 2019;19(1):1–9. doi:10.1186/s12879-019-4387-3
   PubMed Web of Science ®Google Scholar
• Said D, Willrich N, Ayobami O, Noll I, Eckmanns T, Markwart R. The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014–2018): an analysis of data from the national Antimicrobial Resistance Surveillance system. Antimicrob Resist Infect Control. 2021;10(1):1–13. doi:10.1186/s13756-021-00909-8
   PubMed Web of Science ®Google Scholar
• Chamieh A, El-Hajj G, Zmerli O, Afif C, Azar E. Carbapenem resistant organisms: a 9-year surveillance and trends at Saint George University Medical Center. J Infect Public Health. 2020;13(12):2101–2106. doi:10.1016/j.jiph.2019.02.019
   PubMed Web of Science ®Google Scholar